Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL7262025 | 1.00 | CA5A (0.35) | CA5ACA5BALDH1A1LMNASMN1; SMN2 | |
| Nitric Acid SCHEMBL15562819 | 1.00 | CA5A (0.35) | CA5ACA5BALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL62389 | 0.96 | — | — | |
| SCHEMBL9420277 | 0.96 | ALDH1A1 (0.37) | ALDH1A1LMNASMN1; SMN2GSRKDM4E | |
| Ethylene SCHEMBL11768572 | 0.91 | ALDH1A1 (0.34) | ALDH1A1LMNASMN1; SMN2GSRKDM4E | |
| Acetic Acid SCHEMBL11173531 | 0.91 | PTGS2 (0.34) | LMNASMN1; SMN2GSRKDM4EDUSP3 | |
| Nitroglycerin SCHEMBL1746747 | 0.89 | PTGS2 (0.36) | GSR | |
| Nitric Acid SCHEMBL28312897 | 0.89 | THRB (0.45) | — | |
| Acetic Acid SCHEMBL27494476 | 0.86 | PTGS2 (0.35) | ALDH1A1LMNASMN1; SMN2GSRKDM4E | |
| SCHEMBL2728056 | 0.84 | ALDH1A1 (0.42) | CA5ACA5BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6535 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260048181-A1 | ANTIMICROBIAL POLYCARBONATE COATINGS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-02-19 | — | — | US | claimed |
| WO-2025235664-A1 | PURINE NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2025-11-13 | — | — | WO | claimed |
| EP-4625575-A1 | LITHIUM ION BATTERY AND ELECTRIC DEVICE | BYD Company Limited (CN) | 2025-10-01 | — | — | EP | claimed |
| US-20250288607-A1 | METHODS FOR TREATING SEXUAL DYSFUNCTION ASSOCIATED WITH POLYCYSTIC OVARY SYNDROME (PCOS) OR WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-09-18 | — | — | US | claimed |
| US-20250288555-A1 | SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE | EPICENTRX, INC. (US) | 2025-09-18 | — | — | US | claimed |
| US-20250248940-A1 | Biopolymer Formulations for Drug Delivery | 11584022 CANADA INC. (CA) | 2025-08-07 | — | — | US | claimed |
| EP-4597676-A1 | LITHIUM BATTERY AND ELECTRICAL DEVICE | BYD Company Limited (CN) | 2025-08-06 | — | — | EP | claimed |
| US-20250246609-A1 | LITHIUM BATTERY AND ELECTRICAL DEVICE | BYD COMPANY LIMITED (CN) | 2025-07-31 | — | — | US | claimed |
| WO-1992004011-A1 | DOSAGE FORM FOR TIME-VARYING PATTERNS OF DRUG DELIVERY | ALZA CORPORATION (US) | 1992-03-19 | — | — | WO | claimed |
| WO-1992000729-A1 | DOSAGE FORM FOR ADMINISTERING A DRUG TO EFFECT CIRCADIAN THERAPY | ALZA CORPORATION (US) | 1992-01-23 | — | — | WO | claimed |
| US-4952402-A | EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS | ELAN CORPORATION, P.L.C. (IE) | 1990-08-28 | — | — | US | claimed |
| EP-0284849-A1 | Sustained release tablets on the basis of high molecular weight hydroxypropylmethylcellulose and a process for their manufacture | LEK, tovarna farmacevtskih in kemicnih izdelkov, n.sol.o. (SI) | 1988-10-05 | — | — | EP | claimed |
| EP-0251425-A1 | Article for administration of pharmacologically-active substances | HERCON LABORATORIES CORPORATION (US) | 1988-01-07 | — | — | EP | claimed |
| US-4711887-A | HYPOTENSIVE AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-12-08 | — | — | US | claimed |
| US-4369172-A | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose | FOREST LABORATORIES INC. (US) | 1983-01-18 | — | — | US | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
| US-4112115-A | Therapy of leg muscle cramps | COGHLAN CHARLES C | 1978-09-05 | — | — | US | claimed |
| US-3957549-A | PETRIN ACRYLATE, DINITROPROPYL ACRYLATE, ACRYLIC ACID | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1976-05-18 | — | — | US | claimed |